Comparison of Safety and Immunogenicity of a High Dose (5 x 10exp8 TCID50) and a Standard Dose (1 x 10exp8 TCID50) of IMVAMUNE in Healthy Vaccinia-Naive Individuals.
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2012
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions; Pharmacodynamics
- 16 Feb 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 16 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jan 2012 Actual patient number is 91 according to ClinicalTrials.gov.